Impact Biomedical (IBO) Liabilities and Shareholders Equity (2022 - 2026)

Impact Biomedical's Liabilities and Shareholders Equity history runs 5 years deep, the most recent figure standing at $17.1 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 14.79% year-over-year to $17.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $71.8 million (down 45.29% YoY) and the FY2025 annual result came in at $17.4 million, down 14.22% from the prior year.
• Liabilities and Shareholders Equity was $17.1 million for Q1 2026 at Impact Biomedical, down from $17.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $46.7 million in Q3 2024 and bottomed at $17.1 million in Q1 2026.
• A 5-year average of $33.0 million and a median of $44.1 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity rose 3.58% — and 2025, when it sank 61.01%.
• Impact Biomedical's Liabilities and Shareholders Equity stood at $46.5 million in 2022, then retreated by 4.01% to $44.6 million in 2023, then slumped by 54.54% to $20.3 million in 2024, then fell by 14.22% to $17.4 million in 2025, then decreased by 1.83% to $17.1 million in 2026.
• Business Quant data shows IBO's Liabilities and Shareholders Equity at $17.1 million in Q1 2026, $17.4 million in Q4 2025, and $18.2 million in Q3 2025.